Literature DB >> 28399030

Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy.

Chloe Ayres1, Gayanie Ratnayake, Orla McNally, Michael Quinn.   

Abstract

OBJECTIVE: Opportunistic bilateral salpingectomy is now promoted for women at the time of hysterectomy for a benign disease, consequent to the fimbrial end of the fallopian tube emerging as the primary site for carcinogenesis in high-grade serous carcinomas. In high-risk women with an identified germ line mutation, bilateral salpingo-oophorectomy offers the greatest risk reduction for ovarian cancer. Currently, no prospective evidence exists with respect to the effectiveness of opportunistic salpingectomy alone in preventing ovarian cancer. Although it is thought that there is no direct connection between the ovary and its adjacent fallopian tube, we often find remnants of the fimbria adherent to the ovary at the time of surgery. If this tubo-ovarian interface is not separate, then practices such as salpingectomy and radical fimbriectomy may be incomplete, and the effectiveness of this technique as a prophylactic strategy may need reconsideration. We aimed to establish whether there might exist a direct attachment of the fimbria to the ovary by examining this interface in surgically removed specimens.
METHODS: The tubes and ovaries of 20 women undergoing risk-reducing salpingo-oophorectomy were examined using the Sectioning and Extensively Examining the Fimbriated End of the Tubes protocol and p53 immunohistochemistry for lesions suspicious of serous intraepithelial tubal carcinoma.
RESULTS: Three specimens showed fimbria adherent to the ovary at the histopathological analysis. One p53 signature was identified, but there were no occult cancers or serous intraepithelial tubal carcinomas.
CONCLUSIONS: Although only a small study, the findings show that microscopic fimbriae are adherent to the ovary. This relationship challenges the recommendation for bilateral salpingectomy alone for risk-reducing surgery because the primary site of carcinogenesis may be left on the ovary to later develop into a high-grade serous carcinoma. A larger study is needed to assess our findings related to the tubo-ovarian interface and its implications for long-term ovarian cancer development. Until then, caution on using this technique alone in the high-risk patient should be adopted.

Entities:  

Mesh:

Year:  2017        PMID: 28399030     DOI: 10.1097/IGC.0000000000000954

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  IS "OVARIAN" CANCER A MISNOMER? EXPLORING OVARIAN CANCER ORIGINS IN THE MOUSE.

Authors:  Kathleen R Cho
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

2.  Feasibility of Risk Reducing Salpingo-Oophorectomy at the Time of Abdominal Surgery for Correction of Pelvic Organ Prolapse and Urinary Incontinence.

Authors:  Ali Azadi; James A Bradley; Greg J Marchand; Douglas J Lorenz; David Doering; Donald R Ostergard
Journal:  Gynecol Minim Invasive Ther       Date:  2021-01-30

Review 3.  Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

Authors:  Lisa Jeffers; Joanne Reid; Donna Fitzsimons; Patrick J Morrison; Martin Dempster
Journal:  Cochrane Database Syst Rev       Date:  2019-10-09

4.  Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: a 10-year single centre experience from China and a literature review.

Authors:  Ying Chen; Hui Du; Lewen Bao; Wenxin Liu
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

Review 5.  Recommendations for diagnosing STIC: a systematic review and meta-analysis.

Authors:  Joep M A Bogaerts; Miranda P Steenbeek; Majke H D van Bommel; Johan Bulten; Jeroen A W M van der Laak; Joanne A de Hullu; Michiel Simons
Journal:  Virchows Arch       Date:  2021-12-01       Impact factor: 4.535

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.